Oxford, UK – 26 February 2019. OGT, The Molecular Genetics Company, has announced that it is expanding its CytoCell® operations with a move to a new facility in Cambridge, UK. CytoCell, OGT’s fluorescence in situ hybridisation (FISH) probe brand, will be moving into the significantly larger facility on the prestigious Cambridge Science Park, due to expansion of the organisation, current sales volumes and predicted sales growth. In addition to investing in OGT by expanding CytoCell’s operational footprint, OGT’s parent company, Sysmex, is demonstrating its confidence in the UK by establishing the new premises.
OGT’s CytoCell brand provides the largest range of high-quality, reliable, and cost-effective FISH probes on the market and is well known for its comprehensive range, exceptional customer support, service and expertise. Over recent months, OGT has been expanding the direct sales of CytoCell products in Europe and Asia. Staff numbers across the organisation are increasing and a larger space is needed for manufacturing and logistics facilities to match the increased volume of product manufacture and shipment. The new facility will have approximately three times the floor space of the current premises and capabilities to deliver a significant increase in output as the business continues to grow. OGT also plans to create a training and demonstration facility in the new premises to host its customers.
John Anson, CEO of OGT commented, ‘We’re delighted to announce the investment in, and expansion of, our CytoCell operations by Sysmex. Sysmex is committed to growing our business and aligning our commercial synergies. In addition, Sysmex is demonstrating its confidence in the UK’s strong traditional base in Life Sciences. Our ever-growing cooperation with Sysmex delivers the benefits of being part of a larger organisation to our customers, providing them with enhanced services and support.’
In addition to investing in OGT’s CytoCell brand, Sysmex is considering creating a global R&D facility at the premises to evaluate new technologies and pursue collaborations with key opinion leaders, resulting in delivery of innovative new products to the market.
Kenji Tsujimoto Executive Vice President of Technology Strategy at Sysmex Corp. added, ‘Our acquisition of OGT has been, and continues to be, extremely successful. We are very much aligned in our goals and our synergies make for an excellent collaboration. This significant investment in the company is testament to our confidence and desire to further develop OGT’s brands alongside our portfolios’.
OGT anticipates the new facility to be fully operational by May 2019.
OGT, a Sysmex Group company, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists - including CytoCell®, CytoSure® and SureSeq™ ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers - not only by sharing its expertise of 25 years at the forefront of genetic endeavour, but also by working closely with scientists to understand their unique challenges, and to customise its approach to meet their exact needs. Dedicated to improving clinical care, OGT believes that through partnership—together—we’ll achieve more.
For more information on the Company, please visit our website at ogt.com
CytoSure®, SureSeq™ and myProbes®: For Research Use Only, not for use in diagnostic procedures. CytoCell: Some products may not be available in your region.
About Sysmex Corporation
Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 50 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. Sysmex also seeks to leverage its state-of-the-art technologies for cell, gene and protein analysis. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs more than 9,000 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange.
For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/.
Addition of direct-sales territories follows successes across Europe and APAC and provides customers with enhanced local sales and support services.Read
Launch of two NGS panels enables comprehensive detection of genetic abnormalities involved in breast and ovarian cancer, and myeloid disorders.Read
Plasma and tissue sequencing demonstrate clearance of ctDNA correlates with pathologic complete response in breast cancer patients during neoadjuvant treatment.Read